1. Eberhard Ritz,Ivan Rychlík,Francesco Locatelli,Serge Halimi (1999). End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. American Journal of Kidney Diseases, 34(5), 795-808.
2. P Bahman,Tabaei,Abdul Mph,Al-Kassab,Md,Liza Phd,Ilag,Catherine Md,Zawacki,Rn,William Bsn,Herman,Mph Md,Cda Stehouwer,J Lambert,Ajm Donker,Vwm Van Hinsbergh (1997). Endothelial dysfunction and the pathogenesis of diabetic angiopathy. Cardiovasc Res, 24
3. Cda Stehouwer,J Yudkin,P Fioretto,R Nosadini (1998). How heterogeneous is microalbuminuria? The case for 'benign' and 'malignant' microalbuminuria. Nephrol Dial Transplant, 13, 2751-2754.
4. (2012). Subject Index. Frontiers in Diabetes, 243-255.
5. M Brownlee (2005). The pathobiology of diabetic complications: a unifying mechanism. Diabetes, 54, 1615-1625.
6. Sarah Yuan,Robert Rigor (2010). University of California Davis. University of California Davis
7. Konstantin Birukov (2009). Small GTPases in mechanosensitive regulation of endothelial barrier. Microvascular Research, 77(1), 46-52.
8. D Versari,E Daghini,A Virdis,L Ghiadoni,S Taddei (2009). Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care, 32, 314-321.
9. Masashi Yanagisawa,Hiroki Kurihara,Sadao Kimura,Yoko Tomobe,Mieko Kobayashi,Youji Mitsui,Yoshio Yazaki,Katsutoshi Goto,Tomoh Masaki (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332(6163), 411-415.
10. H Ito,Y Hirata,S Adachi,M Tanaka,M Tsujino,A Koike,A Nogami,F Murumo,M Hiroe (1993). Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. Journal of Clinical Investigation, 92(1), 398-403.
11. (1985). Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org(Tech. Rep. Ser, 727(6)
12. M The,Association (2002). Unknown Title.
13. C Stehouwer (2004). Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease. Nephrology Dialysis Transplantation, 19(4), 778-781.
14. B Becker,D Chappell,D Bruegger,T Annecke,M Jacob (2010). Therapeutic strategies targeting the endothelial glycocalyx: acute deficits, but great potential. Cardiovascular Research, 87(2), 300-310.
15. M Potenza,S Gagliardi,C Nacci,' Carratu,Mr,M Montagnani (2009). Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem, 16, 94-112.
16. S Belmadani,Y Park,Z Tang,A Feldman,W Chilian,C Zhang (2001). Effects of ET(A)-and ET(B)-receptor antagonists on regional kidney blood flow, and responses to intravenous endothelin-1, in anaesthetized rabbits. Arterioscler Thromb Vasc Biol, 27(6), 245-248.
17. Rg,A Madden,J Oliver,Tv ; Lewis,Maria Nabinger,Jacques,H Silvaluís,Canani (2008). Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus Claudete M. ZanattaFernando, GerchmanLucas Burttet Gustavo. Diabetes Research and Clinical Practice, 80(2), 299-304.
18. Bg1 Seligman,A Biolo,C Polanczyk,J Gross,N ; Clausell,M Simonson,W Herman (1993). Protein kinase C and protein tyrosine kinase activity contribute to mitogenic signaling by endothelin-1: cross-talk between G protein-coupled receptors and pp60csrc. Diabetes Care, 23(9), 9347-9357.
19. R Caldwell,M Bartoli,M Behzadian,A El-Remessy,M Al-Shabrawey,D Platt (2003). Vascular endothelial growth factor and diabetic retinopathy: pathophys-iological mechanisms and treatment perspectives. Diabetes Metab Res Rev, 19, 442-455.
20. R Lucas,S Magez,De Leys,R Fransen,L Scheerlinck,J Rampelberg,M (2010). Vascular dysfunction in retinopathy-an emerging role for arginase. Brain Res Bull, 81, 303-309.
